| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Community
Forum: Caring and Sharing
Thread: Idiopathic Pulmonary Fibrosis |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 99
|
|
| Author |
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges: 
|
It was approved last year - April if I understand this correctly. But I guess it takes a while before even specialists will consider prescribing it. The trial results that came out early this year probably helped a lot with that - it probably gives them more incentive.
----------------------------------------Best of luck Alan!    |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Given that Intermune is behind this , it's probably just a blatant attempt at self-promotion, but that doesn't mean it might not do some good.
----------------------------------------To mark international Rare Disease Day, InterMune announced its support for the development of a European Patient Charter for people with idiopathic pulmonary fibrosis (IPF). . . . The Charter will see, for the first time, patient advocacy groups and healthcare professionals come together at a European level to campaign for more standardised care and equal access to diagnosis, treatment and after care options for those with IPF in Europe. [Edit 1 times, last edit by twilyth at Mar 24, 2014 9:51:52 PM] |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
That's part of the headline for this story .
----------------------------------------A leading respiratory expert has warned that the UK is sitting on a lung disease ‘time bomb’. Professor Luca Richeldi, a consultant in respiratory medicine at Southampton General Hospital, said idiopathic pulmonary fibrosis (IPF), which is responsible for 5,000 deaths annually, is increasing at a rate of 5,000 new cases a year. The condition, one of a group of disorders known collectively as interstitial lung disease, causes inflammation and scarring of the lung tissue. |
||
|
|
Ajihad
Cruncher Joined: Apr 29, 2008 Post Count: 8 Status: Offline Project Badges: 
|
For at least a generation I have felt that research funds often concentrate on politically selected subjects and are not correctly allocated. One of the reasons I applaud the Gates Foundation for working where progress seems possible. I guess it's less political selected subjects, but more about the topic of profit :-( You can see that in the fact, that pharma companies are constantly developing new medicine for stuff like colds and other diseases that don't really cause severe damage, because they can sell such stuff to a huge number of wealthy customers in the global north, while on the other side, letal diseases that often occur in the poor global south (e.G. Malaria or AIDS) or rare diseases in general get nearly no research funds, because selling medicine for these diseases wouldn't be profitable enough :-( That's why I'm very happy that at least some non profit projects like WCG exist ;-) |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Not really relevant but a nice human interest story .
----------------------------------------Doncaster man's six day China challenge A Doncaster resident is to take on the first ever âTriple China Challengeâ to raise funds for research into rare lung disease. Bill Farley, aged 47, of Barber Close in Armthorpe, set off to the Orient on Sunday, together with 13 teammates, to complete a never-before attempted challenge for the British Lung Foundation. The adventure will see them complete two half marathons, 155km of cycling, and two days trekking on the Great Wall of China over six days. [Edit 1 times, last edit by twilyth at Apr 8, 2014 9:42:05 PM] |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Another drug that seems to be doing well in clinical trials.
----------------------------------------Genkyotex, a developer of selective NOX enzyme inhibitors, announced the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. Collaborators led by Professor Victor Thannickal at the University of Alabama at Birmingham published the results in Science Translational Medicine. Genkyotex is investigating GKT137831 in a Phase 2 trial in patients with diabetic nephropathy, another progressive fibrotic disease. |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Still waiting to see if my Consultant will approve pirfenidone for me
 |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Good luck with that Alan. It would be nice if things moved a little more quicly for you but I guess I'm not telling you anything you don't already know.
---------------------------------------- |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Boehringer will introduce IPF drug by 2016
---------------------------------------- Additionally, Boehringer Ingelheim won FDA’s Breakthrough Therapy status for volasertib for acute myeloid leukaemia (AML), and the agency’s Fast Track designation for nintedanib for idiopathic pulmonary fibrosis (IPF). |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Inhaled pirfenidone might be more beneficial than oral.
---------------------------------------- SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). Our results indicate that very small inhaled doses deliver oral-superior, but short-lived lung levels. To understand if this increased lung dose may improve IPF efficacy, we further demonstrated that only short-lived lung levels are required for maximum pirfenidone activity. Moreover, because these inhaled doses are small, it is anticipated that oral-observed side effects will be substantially reduced. In addition to these observations, characterization of the pirfenidone mechanism suggests that the drug inhibits a single, upstream pro-fibrotic target with strong influence on downstream pathways critical for IPF initiation and disease progression (manuscript in preparation). |
||
|
|
|